Publications

Detailed Information

The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors

Jeon, Y K; Park, C H; Kim, K-Y; Li, Y C; Kim, J; Kim, Y A; Paik, J-H; Park, B-K; Kim, C-W; Kim, Y-N

Issue Date
2007-09-05
Publisher
Wiley-Blackwell
Citation
J Pathol. 2007 Oct;213(2):170-9.
Keywords
1-Phosphatidylinositol 3-Kinase/metabolismAntibiotics, Antineoplastic/*pharmacologyApoptosis/*drug effectsBenzoquinones/*pharmacologyCell SurvivalDown-Regulation/drug effectsDrug Evaluation, PreclinicalHSP90 Heat-Shock Proteins/*antagonists & inhibitorsHerpesvirus 4, Human/*isolation & purificationHumansLactams, Macrocyclic/*pharmacologyLymphoma, B-Cell/metabolism/pathology/virologyLymphoma, Extranodal NK-T-Cell/metabolism/*pathologyMembrane Potential, Mitochondrial/physiologyOncogene Protein v-akt/metabolismSignal TransductionTumor Cells, Cultured
Abstract
NK/T-cell lymphoma (NKTL) is strongly associated with latent Epstein-Barr virus (EBV) infection. Recently, latent membrane protein 1 (LMP1), an EBV oncoprotein, was reported to activate the phosphatidylinositol-3 kinase (PI3K)/Akt pathway for cell survival. Because geldanamycin (GA) and its derivative, 17-allylamino-17-demethoxygeldanamycin (17-AAG), exhibit anti-tumour activity by degrading HSP90 client proteins, including Akt, we investigated the effect of GA and 17-AAG on the survival of NKTL cell lines. EBV-positive NKTL cell lines, Hank-1 and NK-YS, and an EBV-negative NK leukaemia cell line, NK-L, were treated with PI3K and Akt inhibitors, GA, and 17-AAG, and were subjected to apoptosis and cell viability assays, and immunoblot analysis. EBV-positive B-lymphoblastoid cell lines IM9 and LMP1-transfected IM9 (IM9-LMP1) were also included. Hank-1 and NK-YS cell viability was compromised and apoptosis was induced by LY294002 (PI3K inhibitor) or Akt inhibitor II. GA or 17-AAG administration resulted in the apoptosis of NKTL cells, accompanied by Akt and pAkt down-regulation, caspase 3 activation, and mitochondrial membrane potential disruption. The intrinsic level of pAkt was higher in EBV-positive NKTL cells than in EBV-negative NK-L, and GA or 17-AAG decreased the viability of NKTL cells more efficiently than NK-L. Moreover, IM9-LMP1 was more sensitive to Akt inhibitor II or HSP90 inhibitors than IM9. Importantly, GA showed little effect on the viability of normal peripheral NK cells as non-neoplastic counterparts for comparison. In conclusion, this study suggests that the PI3K/Akt pathway is frequently activated in EBV-positive NKTL and that therapeutic modalities based on targeting the PI3K/Akt pathway with HSP90 inhibitors could be useful for achieving NKTL control.
ISSN
0022-3417 (Print)
http://dx.doi.org/10.1002/path.2219
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17768706
Language
English
URI
https://hdl.handle.net/10371/29103
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share